efmitermant alfa

Efmitermant alfa is a recombinant fusion protein developed as a locally acting GDF/activin ligand trap. It is designed to bind and inhibit select proteins in the TGF-beta superfamily, such as myostatin (GDF8) and activins, which are negative regulators of muscle growth. The drug consists of a human follistatin fragment fused via a peptidyl linker to a human immunoglobulin G2 Fc fragment. Efmitermant alfa was primarily investigated for the treatment of rare neuromuscular disorders including Charcot-Marie-Tooth disease and facioscapulohumeral muscular dystrophy, with orphan drug designation granted for these indications. Development was discontinued after phase II trials failed to meet primary endpoints[1][2][3][5][6].